Hypercoagulable state and methylenetetrahydrofolate reductase (MTHFR) C677T mutation in patients with beta-thalassemia major in Kuwait
Affiliations
Affiliations
- Department of Pathology, Faculty of Medicine, Kuwait University, Safat, Kuwait.
Abstract
Introduction: Patients with thalassemia major often present with a hypercoagulable state, the pathogenesis of which is still not understood.
Materials and methods: This study evaluates the risk factors for hypercoagulability in 50 beta-thalassemia major patients and 50 healthy controls. Fasting total homocysteine, protein C (PC), protein S (PS), antithrombin (AT), activated protein C resistance (APCR) and lupus anticoagulant (LA) were assessed. MTHFR C677T mutation was determined.
Results: Significant reductions in PC, PS and AT were noted in patients. Only 4% of the patients had hyperhomocysteinemia. Thirty-two percent of the patients were heterozygous and 4% were homozygous for MTHFR C677T mutation.
Conclusion: The natural coagulation inhibitors PC, PS and AT were significantly reduced in patients with beta-thalassemia major and were thus important risk factors for the hypercoagulable state, but hyperhomocysteinemia and MTHFR mutation do not seem to be significant risk factors for thromboembolic events.
Similar articles
Congenital thrombotic risk factors in beta-thalassemia.
Sipahi T, Kara A, Kuybulu A, Egin Y, Akar N.Clin Appl Thromb Hemost. 2009 Oct;15(5):581-4. doi: 10.1177/1076029608316170. Epub 2008 May 13.PMID: 18480081
Cruciani F, Moramarco A, Curto T, Labate A, Recupero V, Conti L, Gandolfo GM, Balacco Gabrieli C.Clin Ter. 2003 Sep-Oct;154(5):299-303.PMID: 14994919
Prediction of ischemic stroke in young Indians: is thrombophilia profiling a way out?
Chatterjee T, Gupta N, Choudhry VP, Behari M, Saxena R, Ashraf MZ.Blood Coagul Fibrinolysis. 2013 Jun;24(4):449-53. doi: 10.1097/MBC.0b013e32835bfe21.PMID: 23337710
The hypercoagulable state in thalassemia intermedia.
Taher AT, Musallam KM, Inati A.Hemoglobin. 2009;33 Suppl 1:S160-9. doi: 10.3109/03630260903351619.PMID: 20001621 Review.
Cerebral thrombosis in patients with β-thalassemia: a systematic review.
Haghpanah S, Karimi M.Blood Coagul Fibrinolysis. 2012 Apr;23(3):212-7. doi: 10.1097/MBC.0b013e3283502975.PMID: 22322139 Review.
Cited by
Protein C and S levels in patients with Thalassemia intermedia.
Mohammed NS.J Med Life. 2022 Nov;15(11):1415-1418. doi: 10.25122/jml-2021-0316.PMID: 36567848 Free PMC article.
Nigam N, Singh PK, Agrawal M, Nigam S, Gupta H, Saxena S.Cureus. 2020 Sep 30;12(9):e10743. doi: 10.7759/cureus.10743.PMID: 33150118 Free PMC article.
Protein C and Anti-Thrombin-III Deficiency in Children With Beta-Thalassemia.
Abd El Mabood S, Fahmy DM, Akef A, El Sallab S.J Hematol. 2018 May;7(2):62-68. doi: 10.14740/jh392w. Epub 2018 May 10.PMID: 32300414 Free PMC article.
Abd-Elmawla MA, Rizk SM, Youssry I, Shaheen AA.PLoS One. 2016 May 17;11(5):e0155070. doi: 10.1371/journal.pone.0155070. eCollection 2016.PMID: 27187171 Free PMC article.
Pulmonary hypertension associated with thalassemia syndromes.
Fraidenburg DR, Machado RF.Ann N Y Acad Sci. 2016 Mar;1368(1):127-39. doi: 10.1111/nyas.13037. Epub 2016 Mar 23.PMID: 27008311 Free PMC article. Review.